Previous Article | Next Article 
Molecular and Cellular Biology, July 2001, p. 4528-4543, Vol. 21, No. 14
0270-7306/01/$04.00+0 DOI: 10.1128/MCB.21.14.4528-4543.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Site-Specific Recognition of a 70-Base-Pair Element
Containing d(GA)n Repeats Mediates
bithoraxoid Polycomb Group Response Element-Dependent
Silencing
Jacob W.
Hodgson,
Bob
Argiropoulos, and
Hugh W.
Brock*
Department of Zoology, University of British
Columbia, Vancouver, British Columbia, Canada V6T 1Z4
Received 5 March 2001/Returned for modification 30 March
2001/Accepted 23 April 2001
 |
ABSTRACT |
Polycomb group proteins act through Polycomb group response
elements (PREs) to maintain silencing at homeotic loci. The minimal 1.5-kb bithoraxoid (bxd) PRE contains a region required for
pairing-sensitive repression and flanking regions required for
maintenance of embryonic silencing. Little is known about the identity
of specific sequences necessary for function of the flanking regions.
Using gel mobility shift analysis, we identify DNA binding activities
that interact specifically with a multipartite 70-bp fragment (MHS-70)
downstream of the pairing-sensitive sequence. Deletion of MHS-70 in the
context of a 5.1-kb bxd Polycomb group response element
derepresses maintenance of silencing in embryos. A partially purified
binding activity requires multiple, nonoverlapping d(GA)3
repeats for MHS-70 binding in vitro. Mutation of d(GA)3
repeats within MHS-70 in the context of the 5.1-kb bxd PRE
destabilizes maintenance of silencing in a subset of cells in vivo but
gives weaker derepression than deletion of MHS-70. These results
suggest that d(GA)3 repeats are important for silencing but
that other sequences within MHS-70 also contribute to silencing.
Antibody supershift assays and Western analyses show that distinct
isoforms of Polyhomeotic and two proteins that recognize
d(GA)3 repeats, the TRL/GAGA factor and Pipsqueak (Psq), are present in the MHS-70 binding activity. Mutations in
Trl and psq enhance homeotic phenotypes of
ph, indicating that TRL/GAGA factor and Psq are enhancers
of Polycomb which have sequence-specific DNA binding activity. These
studies demonstrate that site-specific recognition of the
bxd PRE by d(GA)n repeat binding
activities mediates PcG-dependent silencing.
 |
INTRODUCTION |
The developmental fate of
parasegments along the antero-posterior axis in Drosophila
is determined by the spatially regulated expression of the homeotic
genes of the Antennapedia complex and the Bithorax complex (BX-C)
(1, 12). Parasegmentally restricted expression of homeotic
genes is temporally regulated in two distinct phases: initiation
(stages 5 to 11) and maintenance (stages 8 to 17). Initiation of
homeotic gene silencing in defined territories occurs because
transiently expressed transcription factors encoded by the segmentation
genes silence homeotic gene expression in specific parasegments. Later
in embryogenesis, maintenance of silencing of homeotic genes requires
the action of Polycomb group (PcG) proteins (53).
Mutations in PcG genes do not affect initiation of silencing but result
in parasegment-selective misexpression of the homeotic genes during the
maintenance phase (36, 54, 55, 58). Maintenance of
activation of homeotic gene expression requires the action of the
trithorax group (trxG) genes (32).
PcG proteins mediate maintenance of silencing at target loci through
complex, modular elements termed PcG response elements (PREs). PREs
have different modes of silencing, monitored using different assays.
PREs were originally defined by their ability to maintain silencing of
gene expression regulated by parasegment-specific enhancers in the BX-C
(55). In embryos, transgenes regulated by endogenous
promoters and parasegment-specific enhancers of homeotic loci show
correct initiation of spatial regulation, but during germband
extension, transgene expression is derepressed owing to the absence of
the PRE sequences required to maintain silencing. Mutations in PcG
genes prevent maintenance of silencing mediated by PREs, showing that
silencing through PREs is PcG dependent (7-10, 23, 38, 45, 46,
55). Immunohistochemistry experiments on polytene chromosomes
(11, 67) and formaldehyde cross-linking experiments show
that PcG proteins are associated with known PREs in vivo (40,
60). PREs also silence adjacent reporters used to select
transgenic flies (7, 9, 18, 22, 55).
A novel repressive mechanism called pairing-sensitive repression is
detected when PREs are in trans. PRE-dependent silencing of
the adjacent mini-white reporter gene, contained in the
transposon, is stronger from homozygous transgenes than from a
heterozygous transgene, presumably because the PREs repress more
efficiently when paired. Normally, expression of homozygous transgenes
is higher than expression of heterozygous transgene because there are
two copies of the transgene rather than one (18, 22, 29, 30). Molecular analysis of PREs shows that the regions
responsible for pairing-sensitive repression are separable from the
regions required for maintenance of embryonic silencing, as has been
shown for the Sex combs reduced PREs (22), the
bithoraxoid (bxd) PRE (51), and the
infra-abominal-2 (iab-2) PRE (50). In the
best-studied case, the shortest fragment from the bxd PRE
that exhibits embryonic silencing and pairing-sensitive repression, the
1.5-kb maintenance (M) element, was shown to consist of a central
661-bp fragment required for pairing-sensitive repression flanked by
sequences required for embryonic silencing (52).
A central question is how PcG proteins recognize PREs site
specifically. No PcG protein binds DNA directly, except for
Pleiohomeotic (PHO) (6). PHO is the Drosophila
homologue of YY1 and recognizes a short consensus sequence found in
many but not all PREs (37). A key observation is that PHO
sites are necessary but not sufficient for the pairing sensitivity of
an engrailed PRE tested in the white repression
assay (6). Mutations of two PHO binding sites in a 160-bp
fragment (C3) from the bxd PRE abolished pairing sensitivity of the white gene, supporting the possibility that PHO can
recruit other PcG proteins to this fragment (62). PHO
sites in the bxd PRE are necessary for silencing of
Ultrabithorax (Ubx) in imaginal discs, but no effect was
reported on maintenance of embryonic silencing (20). PHO
binding sites from the iab-2 regulatory region of
abdominal-A are necessary for pairing-sensitive repression of white but are not sufficient to maintain embryonic
silencing (50). Recently, it has been shown that if PHO is
tethered to a reporter gene, it is unable to silence the reporter,
presumably because it is not sufficient to recruit other PcG proteins
to this site (47). Together, the data suggest that PHO is
necessary for pairing sensitivity and silencing in imaginal discs but
that PHO binding sites by themselves are insufficient to confer
maintenance of embryonic silencing.
The PHO data strongly imply that sites flanking the pairing-sensitive
element in the bxd PRE may recognize other PcG complexes. In
vitro binding assays show that subfragments of the 1.5-kb or M element
of the bxd PRE that lack PHO binding sites recognize binding
activities containing Polycomb (PC) and Posterior Sex Combs (PSC)
(26). In the iab-2 regulatory region, sequences from iab-2 that did not contain PHO binding sites could
confer embryonic silencing on reporter genes, indicating that PREs are complex, modular elements (50). Many PREs contain
d(GA)n repeats, which are recognized by GAGA
factor (GAF) (5, 31, 66) and by Pipsqueak (Psq)
(35). GAF is an antirepressor for many genes (33,
39) and is encoded by Trithorax-like (Trl), a member
of the trxG (17). TRL/GAF colocalizes with PcG proteins at
many PREs (59), which could be explained if trxG response elements and PREs are closely situated (62).
Trl mutations decrease silencing by the Fab-7
PRE, suggesting that TRL/GAF is required for silencing by this PRE
(23). Consistent with this idea, coimmunoprecipitation experiments show that TRL/GAF associates with some PcG complexes that
recognize the bxd PRE (26). Psq is a DNA
binding protein required in oogenesis and eye development (51,
64), but its role in homeotic gene regulation is unknown.
It is important to identify minimum fragments necessary for PRE
function in order to understand the mechanism of site-specific recognition of PREs by PcG-containing DNA binding activities and to
determine how PREs are assembled from modular subunits. In this work,
we analyze a 485-bp region in the 1.5-kb M element that is downstream
of the 661-bp pairing-sensitive region (52), termed DPS
(downstream of Pairing-Sensitive region). We use a gel mobility shift
assay to screen fragments from DPS for DNA binding activities, using
nuclear extract made from Kc cells. One binding site, termed MHS-70,
impairs maintenance of embryonic silencing when deleted from a 5.1-kb
bxd PRE, demonstrating that this sequence is necessary for
PRE function in vivo. Other DNA fragments from within the M element of
the bxd PRE compete for binding to MHS-70, suggesting that
related sites of recognition are located elsewhere in the
bxd PRE. Mutational analysis of MHS-70 shows that in vitro
binding depends on d(GA)3 repeat elements. Mutation of the
d(GA)3 repeat elements in MHS-70 in the context of the
5.1-kb bxd PRE destabilizes embryonic maintenance of
silencing, showing that d(GA)3 elements are required for
PRE function. The increased severity of derepression exhibited by the
MHS-70 deletion compared to the substitution mutants suggests that
other sequences in MHS-70 also contribute to maintenance of silencing.
Fractionation of the nuclear extract shows that distinct binding
activities recognize MHS-70. One partially purified binding activity is
supershifted by antibodies to Polyhomeotic (PH), showing that it
contains at least one PcG protein. Western blot and antibody supershift
analyses of this activity show that distinct isoforms of PH, and two
proteins that recognize d(GA)n repeats, TRL/GAF
and Psq, recognize MHS-70 in vitro. Interestingly, the partially
purified fraction does not contain PC, Suppressor of zeste [SU(Z)2],
or PSC, indicating that we have identified a novel PcG activity which
is distinct from the PRC1 complex. Genetic analysis shows that
mutations in Trl and psq enhance the homeotic
phenotypes of ph. We conclude that TRL/GAF and Psq are
enhancers of PC which have sequence-specific DNA binding activity.
These results suggest that site-specific recognition of the
bxd PRE by d(GA)n repeat binding
activities mediate PcG-dependent silencing.
 |
MATERIALS AND METHODS |
Plasmid vectors and linker substitution mutants.
The BX-C
genomic subclone 3103 containing the 11-kb BamHI
bxd fragment of phage L2212 (2) was digested
with BamHI and HindIII to isolate a 5.1-kb
subfragment of bxd6.5 (Fig.
1A), which was subcloned into pBluescript
KS+ [pBS(KS+)] to generate pBS-3101HB. The
1.5-kb StyI-EcoRI fragment or M element
(designated 2212StR1.6 in reference 8) was subcloned as a
blunt-ended fragment into the EcoRV site of pBS to generate pBS-3103M (Genbank accession number L32205). Restriction fragments generated from the 0.485-kb M fragment (Fig. 1A, DPS) were end repaired, subcloned into the EcoRV site of pBS, and
sequenced. The 70-bp MHS-70 fragment was synthesized as blunt-end
complementary phosphorylated nucleotides and subcloned into the
EcoRV site of pBS. Linker substitutions of MHS-70 (Fig. 5A)
and multiple synthetic repeats (MSR) of d(GA)3,
d(A)8, and d(A)5 (Fig. 6A) were synthesized as
phosphorylated complementary oligonucleotides and subcloned as
blunt-ended fragments into the EcoRV site of pBS. Sequences of the upper strands of wild-type, and mutant MHS-70 and MSR of MHS-70
are shown in Table 1.

View larger version (36K):
[in this window]
[in a new window]
|
FIG. 1.
Identification of binding activities recognizing MHS-70.
(A) Schematic representation of the organization of the bxd
PRE. The start site of Ubx transcription is marked by a bent
arrow, the coordinates of Bender et al. (2) are marked at
the top, and the positions of bxd6.5HH and
bxd5.1BH are indicated. The functional regions of
bxd5.1, S1, M, and S2 are indicated on the second line and
are described in the text. A detailed restriction map of the M element
is shown on the third line. Fragments are named by the first letters of
the restriction enzymes defining them, followed by their length in base
pairs. PSR corresponds to the pairing-sensitive element defined by
Sigrist and Pirrotta (52), and the dark line marked BP
identifies the fragment described by Horard et al. (26).
Small triangles mark the location of PHO binding sites
(20). Open boxes represent binding sites identified in
fragment DPS. Restriction site abbreviations: As, AseI; B,
BamHI; Bg, BglI; H, HindIII; Hf,
HinfI; K, KpnI; Nd, NdeI; P,
PstI; R, EcoRI; S, SalI; Sa,
Sau3A; Sf, SfaNI; St, StyI. (B) Gel
mobility shift analyses of complexes formed at MHS-70 with no protein
(lane 1) or with decreasing amounts of the AS fraction of KcI cell
nuclear extract (lanes 2 to 5). Positions of nucleoprotein complexes
formed are shown on the left. (C) Competitive gel mobility shift
analysis of complexes formed at MHS-70 (with 0.6 µg of the AS
fraction) in the presence of a molar excess of unlabeled, nonspecific
(pBR322 BamHI-SalI 276-bp fragment) and specific
(MSa-100) competitor DNA fragment (shown on top). Complex 2 formation
is sequence specific.
|
|
Cell culture and fractionation of nuclear extracts.
Drosophila Kc1 cells were grown in spinner cultures with
Sf-900 II serum-free medium (Gibco BRL) to a density of 7.5 × 106 cells/ml. Crude nuclear extracts were prepared from
approximately 4.5 × 1010 cells by ammonium sulfate
(AS) lysis of isolated nuclei as previously described (24,
41). All buffers used for protein extraction and fractionation
were freshly supplemented with 1 mM benzamidine-HCl, 1 mM sodium
bisulfite, 0.08% bacitracin, 10 µg of pepstatin per ml, 0.15 mM
bestatin, 0.02% soybean trypsin inhibitor, 2 trypsin inhibitor units
(TIU) of aprotinin, 0.5 mM phenylmethylsulfonyl fluoride, 5 mM KF, 40 µM phenyl arsine oxide, 0.2 mM sodium molybdate, and dithiothreitol
(DTT). The AS precipitate of the nuclear lysate was solubilized in
one-sixth of the packed cell volume in buffer HEMG0.1 (25 mM HEPES-KOH
[pH 7.6], 12.5 mM MgCl2, 1.5 mM DTT, 1 mM EDTA, 1 mM
EGTA, 0.01% Brij 36T, 25 µM zinc acetate, 15% [vol/vol] glycerol,
(0.1 M KCl) and dialyzed against the same buffer for 3 h at 4°C.
The dialysate was stored at
80°C (at a protein concentration of 30 to 40 mg/ml). Approximately 200 mg of the AS fraction was diluted with
buffer HEMG0.0 to the conductivity of buffer HEMG0.1 (25 mM HEPES-KOH
[pH 7.6], 6.25 mM MgCl2, 1.0 mM DTT, 0.1 mM EDTA, 0.1 mM
EGTA, 0.01% Brij 36T, 50 µM zinc acetate, 0.5 mM ATP, 20%
[vol/vol] glycerol, (0.1 M KCl) and applied to a Bio-Rex 70 column
(200/400 mesh, Na+; Bio-Rad) equilibrated with buffer
HEMG0.1 (1.0 by 17.4 cm, 10 mg of protein/ml of resin). The column was
washed with 2.5 column volumes (cv) of buffer HEMG0.1 at 2 cv/hr and
eluted with step gradients of 2.5 cv of buffer HEMG containing 0.18, 0.3, 0.6, and 0.85 M KCl. The Bio-Rex 70 0.6 M KCl fraction (BR0.6) was diluted with buffer HEMG0.085 to the conductivity of buffer HEMG0.085 (buffer HEMG containing 0.085 M KCl) and applied to a Q Sepharose column (Pharmacia) equilibrated with buffer HEMG0.085 (0.7 by 10 cm, 5 mg of protein/ml of resin). The column was washed with 3 cv of buffer
HEMG0.15 at 0.5 ml/min and eluted with step gradients of 3 cv of buffer
HEMG containing 0.3, 0.45, and 0.60 M KCl. All chromatographic
fractions were stored in their corresponding elution buffers at
80°C. DNA binding activity was tested at each fractionation step
using a gel mobility shift assay (21) as described below.
Antibodies and Western blot analysis.
The generation and
purification of rabbit anti-Polyhomeotic Proximal (PHP) and
-Polyhomeotic Distal (PHD) polyclonal antibody have been previously
described (25). Rabbit anti-SU(Z)2 antibody was generated
to an Escherichia coli expressed protein of the 213-amino-acid COOH-terminal region of SU(Z)2 (amino acid residues 1153 to 1365) fused to glutathione S-transferase (GST), using previously described procedures (25). Briefly, a
BglII restriction fragment from the 3' end of the
Su(z)2 cDNA clone (a kind gift from Paul Adler) was
subcloned into the BamHI site of pGEX-3X (Pharmacia) and
expressed in E. coli AD202. The fusion protein was affinity
purified over a glutathione-agarose column and used to immunize New
Zealand White rabbits. Antiserum collected after five booster
immunizations was depleted of anti-GST antibodies by using a Sepharose
4B GST affinity column. The depleted antiserum was affinity purified
over a Sepharose 4B GST-SU(Z)2 agarose column by elution with 10 mM
Na2HPO4-NaOH (pH 12.0)-50% ethylene glycol at
25°C, neutralized with 0.5 M NaH2PO4 (pH
2.5), and dialyzed into phosphate-buffered saline-5% glycerol. Rabbit
anti-TRL/GAF P67 polyclonal antibody was a kind gift from Peter Becker
and Carl Wu. Rabbit anti-Psq antibody (AS1 [27]) was a
kind gift from Celeste Berg. Rabbit anti-PC polyclonal antibodies were
obtained from Patrick O'Farrell. For Western blot analysis, 20 µg of
protein from the AS, BR0.6, and Q Sepharose 0.15 M KCl (QS0.15)
fractions were resolved by sodium dodecyl sulfate-polyacrylamide gel
electrophoresis on a 9% gel and transferred onto nitrocellulose
membranes by using a semidry blotter. The blots were probed with
primary antibodies diluted in 5% nonfat dry milk-Tris-buffered saline
(TBS; 50 mM Tris-HCl [pH 7.6], (150 mM NaCl) at a titers of 1:3,000
(anti- TRL/GAF P67); 1:1,000 (anti-PHP), 1:5,000 (anti-Psq [AS1]),
1:2,000 (anti-PC), and 1:1,000 [anti-SU(Z)2] for 5 h at room
temperature. The blots were subsequently probed with goat anti-rabbit
horseradish peroxidase-conjugated secondary antibody (Pierce) diluted
in 5% nonfat dry milk-TBS at a titer of 1:200,000 for 90 min at room temperature. The blots were washed with several changes of TBS-0.5% Tween 20 (BDH) for 90 min and once with TBS-0.01% Tween containing 1.0 M NaCl for 60 min. After a final wash with TBS for 15 min, the blot
was developed with enhanced chemiluminescence using the Supersignal
West Femto substrate (Pierce).
DNA binding assays.
Restriction fragments were excised with
EcoRI and HindIII and filled in with
-32P-labeled deoxynucleoside triphosphate in a Klenow
reaction. The radiolabeled fragments were desalted in a spin column of
Sephadex G-50 and used as probes in gel mobility shift assays. For
assays of protein fractions, a 15-µl binding reaction mixture
consisting of 3 µl of a 5× binding buffer (125 mM HEPES-KOH) [pH
7.6], 50 µM zinc acetate, 15.625 mM MgCl2, 150 mM KCl,
12.5 mM DTT, 0.05% Brij 36T, 25% glycerol) supplemented with 4%
(wt/vol) Ficoll type 400, 1.2 mM ATP, 2.33 to 2.8 mg of bovine insulin
(zinc crystals; Gibco BRL) per ml, 1 mM sodium bisulfite, 0.5 mM
phenylmethylsulfonyl fluoride, 1.5 µl of poly (dA-dG) · poly
(dC-T) (approximately 600 bp; Pharmacia), 1 µl of DNA probe (25,000 cpm/~0.25 ng of DNA), and various amounts of protein fraction (as
indicated in Results) diluted in buffer HEG0.18 (buffer HEMG0.18
lacking MgCl2) was incubated at 25°C for 20 min
(incubation step) and placed on ice for an additional 20 min. The
reaction mixture was resolved at 110 V (constant voltage) on a 4%
polyacrylamide gel (mono/bis ratio of 40/0.5) in 0.5× Tris-borate-EDTA
(native PAGE), dried, and exposed to X-ray film at
70°C.
In DNA competition binding assays, the radiolabeled probe and 10- or
100-fold molar excess of unlabeled competitor DNA restriction fragments
were added simultaneously to the binding reaction. In gel mobility
supershift assays, antibody recognition of protein-DNA complexes was
tested by adding antibodies at various titers in TBS (as indicated in
Results), and a mixture of 3 µg of biotinylated goat anti-rabbit
antibody (Vector Laboratories) and 1.3 µg of streptavidin (Jackson
ImmunoResearch) preincubated on ice for 60 min, to the DNA binding
reaction after the incubation step. The immune reaction mixture was
incubated at 25°C for an additional 15 min, transferred onto wet ice
for 40 min, and subsequently resolved by native PAGE.
Fly culture, transgenic lines, and antibody staining of
embryos.
Flies were maintained at 22°C on standard
cornmeal-sucrose medium containing Tegosept. The wild-type or mutated
bxd5.1 BamHI/HindIII (pBS-3103BH)
fragments were subcloned after end repair into the filled-in
XhoI site of pCaSpeR4 (43). The PCR template
used to generate
MHS-70 was pBS-3103BH. The primers used were
MHS70-p1 (5'-CCGGCTCGAGCCTGTTGCCTTGGCGGCTCT),
MHS70-p2
(5'-CCGGGCTAGCCATACGCACGGCTGTTAGAA),
MHS70-p3
(5'-CCGGGCTAGCCAAGCGAGAGCTTTTCATAG), and
MHS70-p4
(5'-CCGGGCGGCCGCGAAGCCATAACGGCAGAACC). The 200-bp amplified
product from primer pair
MHS70-p1-
MHS70-p2 was digested with
XhoI and EcoRI and subcloned into pBS, generating pBS-XR. The 450-bp amplified product from primer pair
MHS70-p3-
MHS70-p4 was digested with NheI and
NotI and subcloned into pBS-XR, generating pBS-XN. A 571-bp
BglI fragment in the pBS-3103BH vector was replaced by a
600-bp BglI fragment (containing
MHS-70 isolated from
pBS-XN) to generate the final construct, pBS-3103BH-
MHS70. The
600-bp insert was sequenced to confirm its orientation and recloned
into the XhoI site of pCaSpeR4 UbxlacZ
transformation vector to generate bxd5.1
MHS70.
The 571-bp BglI fragment from the pBS-3103BH vector was
subcloned into pBS, generating pBS-BB. pBS-BB was digested with
PstI and AseI to release the MPA-168 fragment,
end filled with Klenow enzyme, and religated to generate pBS-BB
MPA-168. A 403-bp fragment was excised from vector pBS-BB
MPA-168
with BglI and subcloned into a pBS-bxd5.1BH
vector in place of the wild-type 571-bp BglI fragment and
then recloned into pCaSpeR4 UbxlacZ to generate
MPA-168. pBS-XN was digested with PstI and AseI to release
MPA-168, end filled with Klenow enzyme, and religated. The
double-mutated BglI fragment was subcloned into the
pBS-3103BH vector in place of the 571-bp BglI fragment and
recloned into pCaSpeR4 UbxlacZ to generate bxd5.1
MHS70 +
MPA-168. The mutant MHS70-LS1/9 fragment described above
was end filled with Klenow enzyme and ligated into the newly created
NheI restriction site of pBS-3103BH-
MHS70 to generate
bxd5.1-LS1/9. The construct was sequenced to confirm the
orientation of the insert.
Staged embryos were collected and fixed by standard methods
(36). Murine anti-
-galactosidase antibody (Jackson
ImmunoResearch) was incubated with the transgenic embryos overnight at
4°C. A biotinylated goat anti-murine secondary antibody and a
Vectastain ABC horseradish peroxidase kit (Vector Laboratories) were
used to amplify and detect immune complexes.
 |
RESULTS |
Organization of the bxd6.5 PRE.
The minimal
Ubx parasegment 6 (PS6) regulatory element shown to mimic
the function of the endogenous bxd element in transgenes containing a lacZ reporter fused to the Ubx
promoter is bxd14 (55). It contains a 6.5-kb
PRE, bxd6.5HH (Fig. 1A), a composite element that silences
the UbxlacZ transgene in PS1 to -5 and in odd-numbered PS7
to -13 throughout embryogenesis and enhances the expression of the
transgene in even-numbered PS6 to -12 for 12 h of embryogenesis
(8, 9). The bxd6.5HH element contains an
imaginal enhancer and a shorter 5.1-kb
HindIII/BamHI fragment (bxd5.1HB)
which can be subdivided into two parasegment-specific enhancers, S1
(1.8 kb) and S2 (1.8 kb), and a silencer M element (1.5 kb) that
contains PcG-dependent silencers (Fig. 1A) (8, 9, 44, 52).
The M element contains a 661-bp pairing-sensitive region (PSR)
(52) flanked upstream by a 354-bp fragment we term UPS
(Upstream of pairing-sensitive region) and downstream by a 485-bp
fragment we term DPS (Fig. 1A). Genetic analysis of fragments within
the PSR have identified nonoverlapping sites responsive to the PcG genes E(z), Pc, Pcl, pho, Psc, Scm, and Su(z)2
that mediate maintenance of parasegmental silencing of Ubx
in embryos as well as pairing-sensitive repression of the
white gene (20, 26, 62). Consistent with these
findings, binding sites for PHO located within the pairing-sensitive region and DPS (Fig. 1A, marked in sites BP and MPH-75) have been identified (20). Fragment BP is also recognized by
PC-containing DNA binding activities (26). We decided to
analyze DPS with the goals of identifying minimal fragments recognized
by PH-containing DNA binding activities and to permit detailed
functional analysis of these fragments.
Identification of DPS DNA binding activities.
To identify DPS
DNA binding activities and map their sites of interaction, six
restriction fragments spanning DPS (Fig. 1A, MSa-100, MSf-73, MHS-70,
MAH-74, MHA-93 and MPH-75) were analyzed in a gel mobility shift assay
(21) using AS-fractionated nuclear extract derived from
Drosophila Kc1 cells. We reasoned that results might be more
easily interpreted if nuclear extracts were made from Kc1 cells, an
embryonic mass cell culture that lacks detectable expression of UBX,
rather than from embryos that contain mixed populations of cells
expressing or repressing UBX. Nucleoprotein complexes formed with
fragments within DPS were readily detectable at sites MHS-70 (Fig. 1B,
complexes 1 and 2) and MHA-93 (data not shown) but not at sites
MSa-100, MSf-73, MAH-74, or MPH-75 (data not shown). As shown in Fig.
1C, nonspecific fragments from pBR322 and the MSa-100 fragment did not
inhibit binding to MHS-70, demonstrating that these MHS-70 binding
activities identified are sequence specific. As shown in Fig. 1B,
MHS-70 is recognized by heterogeneous binding activities that are
currently uncharacterized with respect to number and subunit
composition. For convenience, we refer to nucleoprotein complexes of
similar mobilities in band shift assays as complex 1 and complex 2.
Isolation of a MHS-70 binding activity from nuclear extracts.
To characterize the MHS-70 binding activities and determine the
sequence specificity of DNA binding, the Kc1 AS fraction was fractionated by two chromatographic steps, Bio-Rex 70 and Q Sepharose (Fig. 2A
and Materials and Methods). Following
chromatography on Bio-Rex 70, MHS-70 complex 2 binding activities were
separated into the 0.3, 0.6, and 0.85 M KCl fractions, (BR0.3, BR0.6,
and BR0.85), whereas complex 1 binding activities were predominantly in
the 0.6 M KCl fraction (Fig. 2B). The apparent differences in the
relative mobilities of complex 2 formed by each fraction reflect the
heterogeneity of binding activities in the AS fraction.

View larger version (36K):
[in this window]
[in a new window]
|
FIG. 2.
Fractionation and supershift analysis of MHS-70
binding activities. (A) Chromatographic fractionation scheme for MHS-70
binding activities. (B) Gel mobility shift analysis of MHS-70 binding
activities present in Bio-Rex 70 fractions, eluted stepwise with
buffers containing 0.1 to 0.85 M KCl. Lanes 1 and 2, no protein and 0.6 µg of AS fraction, respectively; lane 6, 0.3 µg of BR0.6; lanes 3, 4, 5, and 7, 1.6 µg of the Bio-Rex 70 fractions shown above the gel.
Low mobility complexes migrating close to the origin are detected with
fractions eluted at 0.85 M KCl. (C) Supershift analysis of BR0.3,
BR0.6, and BR0.85. No antibody (No Ab), antibody for PHD ( -PHD),
preimmune serum (Pi), and antibody specific for PHP ( -PHP) at a
titer of 1:37.5 were incubated in the binding reactions of the Bio-Rex
70 fractions to MHS-70 in the presence of secondary antibody (2° Ab),
and changes in mobility were monitored in the gel shift assay. Partial
supershifts of complex 2 are clearly detected in BR 0.6 and are not
detected in BR0.3, and are weakly detected in BR0.85. (D) Mobility
shift analysis of QS0.15, QS0.3, QS0.45, and QS0.6 with MHS-70. Lanes 1 and 2, no protein and 0.3 µg of BR0.6 respectively; lanes 3 to 6, 0.25 µg of protein from each Q Sepharose fraction. The MHS-70 binding
activity is only detectable in QS0.15. (E) Supershift analysis of the
QS0.15 binding activity (0.25 µg of protein) with anti-PH antibodies
(lanes 4 to 6 and 12 to 14) at titers of 1:75 (lanes 4 and 12), 1:37.5
(lanes 5 and 13), and 1:10 (lanes 6 and 14). Both anti-PH antibodies
but not the equivalent titer of preimmune serum (lanes 8 to 10) cause
significant supershifts of complex 2.
|
|
To determine if the MHS-70 binding activities contained a PcG protein,
BR0.3, BR0.6, and BR0.85 were analyzed by supershift assays using
antibodies to PH (25). Two different antibodies to PH
caused a readily detectable supershift of complex 2 from BR0.6 but not
from BR0.3 and weakly from BR0.85 (Fig. 2C). The same activity was
tested for the presence of PC and SU(Z)2. Neither PcG protein was
detected (data not shown). The data show that the complex 2 binding
activities present in BR0.6 contain at least one PcG protein. None of
the Bio-Rex fractions analyzed contain detectable PH, PC, or SU(Z)2 in
complex 1.
BR0.6 was subsequently fractionated on Q Sepharose, and as shown in
Fig. 2D, the MHS-70 binding activities were recovered in the 0.15 M KCl
fraction (QS0.15). Complex 2 formed by QS0.15 had a mobility slightly
higher than that of the BR0.6 complex 2, whereas complex 1 had a
mobility slightly lower than that of BR0.6 complex 1 (Fig. 2D, lanes 2 and 3). To confirm that the partially purified MHS-70 binding
activities present in QS0.15 still retained PH, supershift assays were
performed in the presence of titered amounts of two PH antibodies. As
shown in Fig. 2E, both antibodies clearly supershift complex 2, consistent with the enrichment of PH-containing DNA binding activities
in QS0.15. As expected, complex 1 is not supershifted, suggesting that
it does not contain detectable PH.
Site specificity of M element recognition by QS0.15 binding
activities.
To determine if the interaction of QS0.15 binding
activities with the M element was site specific, a competitive gel
shift assay was performed using fragments derived from DPS and PSR
(Fig. 3A). As expected, the formation of
complex 2 is completely inhibited by a 100-fold excess of unlabeled
MHS-70, but formation of complex 1 is partially inhibited (Fig. 3B).
Two other competing fragments, MHA-93 and MSP-61, partially inhibit
complex 2 formation (Fig. 3B), showing that both sites contain
sequences related to MHS-70. No other fragment from DPS or PSR of the M
element competed for binding. These results indicate that MHS-70 is the
predominant binding site of the three distinct sites within the M
element recognized by binding activities present in QS0.15.

View larger version (57K):
[in this window]
[in a new window]
|
FIG. 3.
Competitive gel mobility shift analysis of the QS0.15
activity with M element fragments. (A) DNA fragments from the
bxd M element, indicated on the top line, were used as
competitors in the binding reaction of 0.25 µg of QS0.15 with MHS-70.
Abbreviations for restriction enzymes and nomenclature of fragments are
given in the legend to Fig. 1A, with the exception of Bf
(BfaI). Fragments from the PSR are indicated above the line.
(B) Competitive gel mobility shift analysis of complexes formed at
MHS-70 in the presence of a molar excess of unlabeled fragments from
the bxd M element. As expected, MHS-70 completely inhibits
the formation of complex 2. Partial inhibition of complex 2 formation
is detected with fragments MHA-93 and MSP-61 (marked with asterisks).
|
|
MHS-70 is required for PRE function in embryos.
To test if the
MHS-70 fragment identified in the in vitro binding assay was required
for PRE function, a germ line transformation assay was conducted.
Transgenic lines containing a UbxlacZ reporter fused to a
wild-type bxd5.1 PRE or an MHS-70 deletion mutant of bxd5.1 PRE (
MHS-70) were tested for the ability to
maintain silencing in anterior parasegments of wild-type
wiso embryos (Materials and Methods).
The bxd5.1 transgene confers complete maintenance of LacZ
expression in PS6 to PS13 and silencing in PS1 to PS5 until late embryogenesis (stage 16) in 2 of 10 lines examined (Fig.
4A) and nearly complete maintenance (with
the exception of spotty ectopic expression in the head and thorax) in 8 of 10 lines (Fig. 5C). Because the
supershift analysis showed that complex 2 contained PH, it was
necessary to test if mutations in ph would cause
misexpression of bxd5.1 UbxlacZ. As shown in Fig.
4B, embryos heterozygous for ph2 (a viable
deletion that results in a fusion of the phP and
phD transcription units to yield one functional
but abnormal protein [48]) showed clear misexpression of
LacZ in PS1 to PS5. Because the PHP-specific antibody also supershifts
complex 2, an inversion that affects phP but not
phD (ph409
[13]) was tested for its effect on bxd5.1
UbxlacZ. Misexpression of LacZ was detected in PS1 to PS5,
albeit at a much lower level than that seen for
ph2, showing that PHP has a role in maintenance
of bxd5.1 UbxlacZ silencing (Fig. 4C). Presumably
phD can partially compensate for the loss of
phP.

View larger version (63K):
[in this window]
[in a new window]
|
FIG. 4.
Mutational analysis of bxd5.1
UbxlacZ expression in germband-extended embryos.
Germband-extended embryos are mounted anterior to the left, dorsal side
up. Expression of LacZ was detected immunohistochemically. The anterior
boundary of PS6 is marked with an arrowhead. The wild-type
bxd5.1 UbxlacZ reporter, consisting of the 5.1-kb
bxd PRE, the Ubx promoter, and the
lacZ and white reporters flanked by P
element long terminal repeats, is shown below the figure, with the DPS
fragment expanded to show detail. The DPS fragment is indicated below
each panel to show if it is wild type (A to C) or to show the positions
and numbers of deletions in mutant constructs (indicated by parentheses
in panel D to F). The same bxd5.1 UbxlacZ
reporter, which exhibits complete silencing anterior to PS6, is used in
panels A to C. (A) Wild-type embryo from a line exhibiting complete
silencing of the reporter in PS1 to PS5 and in the head. (B)
ph2 mutant embryo, showing partial derepression
of bxd5.1 in PS1 to 5 and in the head. (C)
ph409 mutant embryo, showing weak derepresion of
bxd5.1 in PS 1 to 5. (D) bxd5.1 MHS-70 embryo
in a wild-type background showing partial derepression of the reporter
in PS1 to PS5. (E) bxd5.1 MPA-168 embryo exhibiting a
derepression pattern similar to that seen in
bxd5.1 MHS-70. (F) bxd5.1 MHS-70 + MPA-168 embryo showing a derepression pattern similar to that seen
in either single mutant (compare to panels D and E). Notation is as for
Fig. 1A.
|
|

View larger version (41K):
[in this window]
[in a new window]
|
FIG. 5.
Gel shift and in vivo analysis of MHS-70 linker-scanning
mutations. (A) Schematic representation of MHS-70 and mutated
derivatives. Details of mutations are given in the text. The sequences
of interest are marked in the top line and schematically represented in
the second line. Sites of mutations are indicated by filled regions in
the schematic representations of mutated MHS-70 fragments in lines 3 to
7. Coordinates of the substitution sites are shown on the right in
parentheses. (B) Mobility shift analysis of MHS-70 mutants using 0.25 µg of QS0.15. The identities of mutant fragments used in each lane
are shown in panel A. Complex 2 formation is abolished by combined
substitutions of the d(GA)3 repeats. (C) Derepression
caused by d(GA)3 substitution mutations of MHS-70 in
bxd5.1 PRE. Conditions and reporters are explained in the
legend to Fig. 4. The anterior boundary of PS6 is marked with a large
arrowhead. The MHS-70 fragment is schematically represented below each
panel. (i) bxd5.1 UbxlacZ from a line exhibiting
spotty misexpression in PS1 to PS5 and partial derepression in the
head. The PS6 boundary is maintained. (ii) bxd5.1
UbxlacZ mutant for two d(GA)n sites
of MHS-70, LS-1/9 (illustrated in Fig. 5A). Note the clear derepression
in PS1 to PS5 in a distinct subset of cells (small arrowheads), plus
increased derepression in the head.
|
|
In bxd5.1
MHS-70 transgenic lines, initial expression of
LacZ is identical to that of bxd5.1. By germ band extension,
misexpression of LacZ is detected in PS1 to PS5, and this misexpression
persists throughout embryogenesis in five of six lines tested, showing that MHS-70 is essential for embryonic maintenance of silencing in the
context of bxd5.1 (Fig. 4D).
Because the competition analysis identified other sites related to
MHS-70, we tested a deletion of MPA-168 which includes the competing
fragment MHA-93 and the adjoining fragment MPH-75 (containing three PHO
binding sites). Deletion of MPA-168 caused derepression of LacZ to an
extent similar to that seen in
MHS-70 in five of six lines tested
(Fig. 4E). However, in six of six lines tested, deletion of both MHS-70
and MPA-168 showed the same extent of LacZ misexpression as observed
for each individual deletion (Fig. 4F). Therefore, the
bxd5.1 PRE function conferred by the MHS-70 and MPA-168
fragments is neither additive nor synergistic, suggesting that there is
one functional unit of PRE activity in this region. These results show
that MHS-70 and MPA-168 are required for embryonic maintenance of
silencing in the context of bxd5.1 PRE.
Sequence specificity of MHS-70 recognition by QS0.15 binding
activities.
To characterize the sequence elements in MHS-70
recognized by binding activities present in QS0.15, substitution and
deletion mutants of MHS-70 were tested for binding in a gel shift
assay. Inspection of the sequence of MHS-70 showed a complex
arrangement of three distinct repeat elements (Fig. 5A). These include
two direct repeats of d(GA)3 elements flanking a central
inverted d(GA)3 element, which constitute binding motifs
for TRL/GAF (5) and Psq (35). Interspersed
between the d(GA)3 repeats are two d(A) tracts in opposite
orientations [Fig. 5A, d(A)8 and d(A)5(G)] as well as three direct
repeats of a d(AGAGC) element.
Deletion of one of the terminal d(GA)3 sequences diminished
the formation of complex 2 but did not affect the formation of complex
1 (Fig. 5B, lane 3), indicating a requirement of either this repeat
element or a full-length fragment for stable binding. Substitution of
the two remaining d(GA)3 sequences in the truncated fragment eliminated the formation of complex 2 and caused a twofold reduction in complex 1 formation (Fig. 5B, MHH-1/5), strongly suggesting an essential role for multiple d(GA)3 repeats.
As expected, substitution of both terminal d(GA)3 sequences
(Fig. 5B, LS-1/9, lane 5) in the full-length fragment completely
abolished complex 2. These results show that at least two
d(GA)3 repeats are essential for complex 2 but not complex
1 formation and also indicate that MHS-70 might be a multipartite
recognition site.
The contribution of the other repeat elements was tested by a dual
substitution of the central inverted d(GA)3 sequence plus the d(A)8 sequence (Fig. 5B, LS-3/5, lane 7), which caused
a significant reduction in the formation of both complexes 1 and 2. Mutation of both d(A) tracts (Fig. 5B, LS3/6-7, lane 6) caused a
similar reduction in formation of both complexes, suggesting that the d(A) tracts alone or in conjunction with a d(GA)3 sequence
also contribute to the formation of complexes 1 and 2. Mutation of the
three d(AGAGC) direct repeats (Fig. 5B, LS-4/6/8, lane 8) reduced the formation of both nucleoprotein complexes to an extent similar to that of the dual substitution of the d(GA)3 plus
d(A)8 sequence (Fig. 5B, compare lane 8 to 7). These
results demonstrate that MHS-70 is a multipartite, sequence-specific
binding site and define the contribution of the distinct repeat
elements, d(GA)3, d(A) tracts, and d(AGAGC) to
the formation of complexes 1 and 2.
Mutations of d(GA)3 repeat elements reduce PRE
activity.
The foregoing evidence shows that the LS-1/9 mutations
which affect the proximal and distal d(GA)3 repeats of
MHS-70 abolish complex 2 formation in vitro. To test the contribution
of these d(GA)3 repeats for PRE function in vivo, we
investigated the effects of the LS-1/9 mutations in the context of the
bxd5.1 UbxlacZ transgene. In four of four lines
that carried the LS-1/9 mutations, there was partial derepression of
the reporter in a small number of cells in the ventral ectoderm in
germband-extended embryos in PS1 to PS5 and relatively strong
derepression in the head (Fig. 5C). This derepression is more evident
in lateral than medial sections. This pattern of derepression is
distinct from the bxd5.1
MHS-70 mutant phenotype and was
not observed in any bxd5.1 UbxlacZ control lines,
including those which show spotty misexpression in PS1 to PS5 (an
example is shown in Fig. 5C). These results establish a role for
d(GA)3 repeats in PRE function in vivo.
Analysis of multiple copies of MHS-70 repeat elements.
To
further define the roles of the MHS-70 repeat elements in the
recognition of QS0.15 binding activities, the abilities of double-stranded synthetic oligomers containing multiple copies of
d(GA)3, d(A) tracts, and d(AGAGC) repeat
elements (as shown in Fig. 6A) to bind
QS0.15 activities were tested in a gel shift assay. Oligomers
containing several copies of the three d(GA)3 repeats
[Fig. 6B, (GA)3 × 3] form the low-mobility complex 2 but not
the high-mobility complex 1. Conversely, oligomers containing five
copies of d(A)8 plus the distal d(AGAGC) repeat
[Fig. 6B, (A)8 × 5] form complex 1 but not complex 2. However,
oligomers containing nine copies of the d(A)5(G) plus the proximal
d(AGAGC) repeat [Fig. 6B, (T)5 × 9] form both
complexes 1 and 2. In competitive binding studies carried out with each
of these oligomers to determine their ability to compete with MHS-70
(Fig. 6C), both (GA)3 × 3 and (T)5 × 9 oligomers inhibited
the formation of complex 2. The (A)8 × 5 oligomers caused a
significant reduction in the formation of complex 2. However, all three
oligomers caused an approximately twofold reduction in the formation of
complex 1 (Fig. 6C).

View larger version (49K):
[in this window]
[in a new window]
|
FIG. 6.
Gel shift analysis of MHS-70 MSR elements. (A) Schematic
representation of oligomers containing MSR elements used in binding
studies. Lines 1 and 2 are the same as in Fig. 5A; lines 3 to 5 show
the sequences used to construct oligonucleotides. Sequences of the
oligonucleotides are given in Table 1. (B) Mobility shift analysis of
oligonucleotides derived from MHS-70 with 0.25 µg of QS0.15.
Identities of the oligonucleotides are shown in panel A, and
coordinates of the repeat elements are shown on the right in
parentheses. Complex 2 is formed at (GA)3 × 3 and (T)5 × 9, and complex 1 is formed at (A)8 × 5 and (T)5 × 9. (C)
Competitive mobility shift assay. Molar excesses of the
oligonucleotides shown in panel A were used as competitors for the
binding of 0.25 µg of QS0.15 to MHS-70. (GA) 3 × 3 and
(T)5 × 9 abolished the formation of complex 2. The (A)8 × 5 oligomer did not inhibit the formation of complex 2.
|
|
These experiments define at least two forms of both MHS-70 complex 1 and 2 binding activities in QS0.15. Both d(GA)3 repeats and
d(A)5(G)/proximal d(AGAGC) are critical elements for the complex 2 binding activities. They also suggest that the complex 1 binding activities interact with MHS-70 through multiple recognition sequence elements.
Complex 2 binding activities coelute with PH, TRL/GAF, and
Psq.
The results of the sequence-specific analysis above suggests
that d(GA)n-specific binding factors are present
in complex 2. Therefore, antibodies directed against two nuclear factors that bind d(GA)n sequences, TRL/GAF and
Psq (5, 35), were tested in binding reactions with MHS-70.
Preimmune serum had no effect on the mobility of complexes 1 and 2 (Fig. 7A, lanes 7 to 9). In the presence
of increasing amounts of antibody to TRL/GAF, the mobility of complex 2 was significantly retarded, migrating close to the sample well (Fig.
7A, lanes 3 to 5). Antibodies to Psq caused a modest but detectable
retardation of complex 2 (Fig. 7A, lanes 11 to 13). Neither of these
antibodies altered the mobility of complex 1 (Fig. 7A). These results
show that complex 2 contains detectable levels of TRL/GAF and Psq. The
significantly reduced mobility of complex 2 in the presence of
anti-TRL/GAF antibody presumably results from the ability to induce
multimeric aggregates of DNA-TRL/GAF complexes (15, 66).
To show that the complexes formed by MHS-70 and the competing oligomers
were equivalent, the formation of complex 2 with synthetic oligomers was tested with antibodies to TRL/GAF, PH, and Psq. As shown in Fig.
7B, antibodies to PH, TRL/GAF, and Psq, but not preimmune serum,
supershifted complex 2 in both the (GA)3 × 3 and d(T)5 × 9 binding reactions.

View larger version (36K):
[in this window]
[in a new window]
|
FIG. 7.
Supershift and Western analysis of QS0.15. (A) Secondary
antibody (2° Ab) in the absence or presence of primary antibodies to
PH ( -PHP), TRL/GAF ( -TRL), or Psq ( -Psq) or preimmune serum
(Pi) was incubated in binding reactions of 0.25 µg of QS0.15 with
MHS-70, (GA)3 × 3, or (T)5 × 9, and the nucleoprotein
complexes were examined in a mobility shift assay. Lanes 1, 15, and 23 no protein; lanes 2, 16, and 24, no antibody ( Ab); lanes 6, 10, 14, 17, 22, 25, and 30, only secondary antibody (2° Ab). In the MHS-70
binding reactions, -TRL titers were 1:240 (lanes 3), 1:120 (lane 4),
and 1:60 (lane 5); Pi and -Psq titers were 1:30 (lanes 7, and 11),
1:10 (lanes 8 and 12), and 1:7.5 (lanes 9 and 13). In the (GA)3 × 3 or (T)5 × 9 binding reactions, -PHP was used at a titer of
1:10 (lanes 18 and 26), -TRL was used at 1:60 (lanes 20 and 28), and
-Psq or Pi was used at 1:7.5 (lanes 21 and 29 or lanes 19 and 27).
Antibodies to TRL and PHP caused a strong supershift in reactions of
all fragments tested, and anti-Psq caused a detectable, partial
supershift in reactions of the same fragments. (B) Western analysis of
20 µg of protein derived from AS, BR0.6, and QS0.15 fractions
described in Fig. 2A. The fractions were separated by SDS-PAGE on a 9%
gel, transferred to nitrocellulose, and probed with the antibodies
indicated in panel A as described in Materials and Methods. Specific
isoforms of each protein were enriched for and detected in QS0.15 are
shown on the right of each gel; positions of protein molecular mass
markers (in kilodaltons) (Sigma) are shown on the left.
|
|
PHP (25), TRL/GAF (3), and Psq
(27) have multiple isoforms. To determine which of these
isoforms are potential components of complex 2, Western analysis of the
AS, BR0.6 and Q0.15 fractions was undertaken. Q0.15 is enriched for
isoforms of TRL/GAF P67 plus TRL/GAF P54, PHP105 plus PHP64, and Psq
P70 (Fig. 7B). Taken together with the antibody supershift analysis,
these results show that the distinct isoforms of TRL/GAF, PHP and Psq
coelute with complex 2 and suggest that these isoforms constitute
potential subunits of complex 2 binding activities. It has been
previously shown that the full-length isoform of PHP, PHP-170,
coimmunoprecipitates with the PcG proteins PC, PSC, SU(Z)2, and SCM
(19, 34, 49, 60). Western analyses of the three fractions
described above show that there are no detectable levels of PC, SU(Z)2
(Fig. 7B), PSC, or Sex Combs on Midleg (SCM) (data not shown) in Q0.15,
indicating that these PcG proteins do not coelute with complex 1 and 2 binding activities. These results suggest that the complex 2 activity is a novel PcG activity containing distinct isoforms of PHP, TRL/GAF, and Psq.
Genetic tests of Trl and psq function in
PRE-mediated silencing.
Trl null or hypomorphic alleles
(Trl13C, Trl62, and
Trl85) do not affect maintenance of silencing in
vivo by bxd5.1 UbxlacZ (data not shown), in
agreement with results previously obtained (26). Similarly, embryos mutant for psqRF13 (deletion
of psq) and Df(2R)psq-lola
18 (deletion of
psq, termed psqlola hereafter)
(27) show wild-type bxd5.1 UbxlacZ
silencing (data not shown). One potential reason for these results is
that maternally deposited Trl or psq protein or
mRNA rescue the effects of absence of zygotic proteins on embryonic
silencing (4, 27).
Genetic interactions between PcG genes are monitored by the enhancement
of PcG mutations, providing a sensitive genetic assay for genes
required in PcG-mediated silencing (52). Therefore, we
tested the ability of Trl and Psq mutations to
enhance the extra sex combs phenotype of ph. It has
previously been shown that Trl enhances the extra sex combs
phenotype of Pc (59). Similarly, we observed
that Trl62 enhances the extra sex combs
phenotype of ph2 and
ph409 (Table 2;
Fig 8). We also tested the effects of
psqlola-
18 and psq2403
on enhancement of ph2 and
ph409. As shown in Table 2, there is strong
enhancement of the expressivity of the extra sex combs phenotype. These
results are consistent with a role for TRL/GAF and Psq in PcG-mediated
silencing of homeotic loci and indicate that TRL/GAF and Psq are
enhancers of PC which have sequence-specific DNA binding activity.

View larger version (59K):
[in this window]
[in a new window]
|
FIG. 8.
Trl and psq mutations enhance the
extra sex combs phenotype of ph mutants. Wild-type
Drosophila males have two sex combs (marked by arrowheads):
one on each first leg (prothoracic leg) (A) and absent on the second
(mesothoracic) (B) and third (metathoracic) (C) legs. Males hemizygous
for ph mutations exhibit posterior homeotic transformations
where the second and third legs are frequently transformed into the
first, thus increasing the total number of sex combs per male fly. Male
flies transheterozygous for trl or psq and
ph mutations exhibit an enhancement of the extra sex combs
phenotype of ph. For example, ph2/Y;
Trl62/+ males always exhibit sex combs on the
first legs (D), frequently on the second legs (E), and sometimes on the
third legs (F).
|
|
 |
DISCUSSION |
Our results show that specific DNA binding activities recognize
distinct fragments of the bxd1.5 M element in vitro and that two of these fragments, MHS-70 and MPS-168, are necessary for PRE
function in vivo. Detailed analysis of the binding requirements of
MHS-70 show that this binding site is multipartite and involves repeats
of d(GA)3, d(A) tracts, and d(AGAGC) sequences. A partially purified activity recognizing MHS-70 contains specific isoforms of two
d(GA)n recognition factors, TRL/GAF and Psq, and the PcG protein PH which have not been identified in any previously characterized PcG protein complex. The d(GA)n
sequences are required for in vivo function of the bxd5.1
PRE, but other sequences also contribute to function of the MHS-70
element. We show that TRL/GAF are enhancers of PcG mutations with
sequence-specific binding activity, raising the possibility that these
proteins recruit PcG proteins to PREs. Below, we discuss the
implications of these results for PRE structure and function.
Multipartite structure of the MHS-70 binding site.
Inspection
of the MHS-70 sequence revealed a complex arrangement of three distinct
repeat elements likely to be important for QS0.15 binding activities:
d(GA)3, d(A) tracts, and d(AGAGC). In a competitive
inhibition gel shift assay, the contribution of each repeat element was
tested by linker-scanning mutagenesis. No single mutation inhibited
binding (J. W. Hodgson and H. W. Brock, unpublished results).
As shown in Results, combined substitution of the repeat elements in
MHS-70 greatly reduced or abolished binding of the activities present
in QS0.15. These observations could be explained if multiple copies of
the repeat elements were required for MHS-70 recognition. In this case,
mutations of individual sites might lower the affinity of binding but
not abolish it. Alternatively, protein-protein interactions between
factors bound to multiple copies of these repeat elements might
stabilize weak protein-DNA interactions at single repeats. Another
possibility is that binding to the MHS-70 fragment depends on
conformation of the DNA, and single mutations have little effect on
conformation adopted by the nucleoprotein complexes. In this context,
it should be noted that TRL/GAF binds DNA as multimers, that binding to repeated sites is strongly favored over binding to single sites, and
the interaction involves DNA distortion (31, 66).
Experiments in which multiple sites were mutated support the idea that
MHS-70 is a multipartite binding site. Mutation of the two terminal
d(GA)3 repeats in LS-1/9 abolishes binding by QS0.15
complex 2 activity (Fig. 5B, lane 5), whereas mutation of either
repeated copies of the d(A) tracts or d(AGAGC) significantly reduced
binding. These results are consistent with previous results obtained in
an immunoprecipitation assay with the BP fragment (illustrated in Fig.
1) that showed it was necessary to mutate two
d(GA)n sequences in order to abolish binding by
activities containing PC (26).
The results of the binding assays with oligomers containing multiple
copies of unique arrangement of d(GA)3 repeats and the d(A)8/d(AGAGC) element indicated that QS0.15
contains distinct binding activities. These results show that the
d(GA)n repeats are sufficient for complex 2 formation (Fig. 6B) and that the (A)8 × 5 construct is sufficient
for complex 1 formation (Fig. 6B), strongly supporting independence of
binding. Surprisingly, the d(T)5 × 9 oligomer can form complexes
1 and 2, suggesting additional independent modes of DNA recognition by
activities present in QS0.15. The ability of antibodies to TRL/GAF and
Psq to supershift d(T)5 × 9 complex 2 suggests that DNA
recognition may involve either (i) the multivalent recognition of
multiple copies of the minimum d(GAG) trinucleotide in the repeat unit, d(AAAAAGAGCG), by TRL/GAF (15, 65) or DNA
conformation (27) or (ii) DNA bending by d(A) tracts in
the d(T)5 × 9 repeat unit, d(AAAAAGAGCG)
(56). Therefore, it is possible that complex 1 and
complex 2 represent two mutually exclusive nucleoprotein conformations. The precise relationships between these three potential binding activities are currently being analyzed with more highly purified protein fractions (Hodgson and Brock, unpublished).
In vivo analysis of MHS-70 function.
We chose to examine the
effect of the MHS-70 deletion in the context of the bxd5.1
PRE because this element shows more stable and longer-lasting embryonic
silencing and less line-to-line variation than the M element alone.
Therefore, results of small mutations in the context of
bxd5.1 are easier to interpret, the main complications being
conveyed by the presence of redundant recognition sequences in
bxd5.1. However, it is important to note that competition
studies revealed that the only binding fragments that competed for
MHS-70 binding activity are found in the M element (Fig. 3 and results not shown).
Mutation of the terminal d(GA)3 sequences within MHS-70
abolished QS0.15 complex 2 activity in vitro, but the effect of these mutations on derepression of the reporter in germband-extended embryos
was less severe than that of the deletion of MHS-70. The simplest
explanation for this result is that other sequences in MHS-70
contribute to silencing in vivo, including the poly(A) tracts that bind
complex 1 activity and the d(AGAGC) repeats that bind
complex 1 and 2 activities. It will be important to test these
possibilities directly. We cannot rule out the possibilities that the
MHS-70 deletion changes the spacing, or changes the rotational position
or flexibility of the DNA, whereas the point mutations in the
d(GA)3 repeats do not. Our data show a requirement for d(GA)3 sites in conjunction with other MHS-70 repeat
elements in vivo.
These in vivo experiments demonstrate a direct role for the
d(GA)3 repeats in maintenance of silencing by a PRE.
Recognition of MHA-93 may be involved in the maintenance of silencing,
because MHA-93 contains d(GA)n repeats and
competes with MHS-70 in binding reactions of activities present QS0.15
(Fig. 3B). If so, mutation of the d(GA)n repeats
in MHS-70 may be compensated for by the presence of neighboring
d(GA)n sites in MHA-93, thus lessening the
effects of the d(GA)3 mutations in MHS-70. Our in vivo data
suggest that only one unit of PRE function exists in the region
containing MHS-70 and MPA-168, because deletions of these fragments by
themselves or in combination have similar rather than additive or
synergistic effects on derepression of the bxd5.1
UbxlacZ (Fig. 4). The MHS-70 and MPA-168 fragments have only
d(GA)n repeats in common, which suggests an interaction between activities recognizing
d(GA)n sequences in MHS-70 and MPA-168 that is
required for embryonic silencing mediated by DPS.
The role of TRL/GAF and Psq in PcG-mediated silencing.
The two
proteins known that bind d(GA)n repeats are
TRL/GAF and Psq. Our in vitro binding studies assay the ability of
preformed complexes that have been extracted from chromatin and the
nuclear matrix to bind naked DNA and therefore do not directly address
how TRL/GAF and Psq function in vivo. An attractive model is that in
vivo, one or both of these proteins bind the d(GA)n repeats and recruit PcG proteins to the
MHS-70 fragment to assemble a functional repressive complex.
Alternatively, TRL/GAF or Psq could bind as part of a preassembled factor.
Because TRL/GAF antagonizes repressors, it is surprising that TRL/GAF
might have a role in repression by PREs. Chromatin immunoprecipitation experiments show that PcG and TRL/GAF proteins colocalize in vivo (59), but this result could be explained if trxG and PcG
response elements were intermingled (62). TRL/GAF
coimmunoprecipitates with PC, providing independent evidence for the
existence of complexes containing PcG proteins and the TRL/GAF
(26). There are several reports that Trl
mutations permit derepression of reporters mediated by PREs in
transgenic flies, but these effects are often line specific and allele
specific, affect repression in imaginal discs, or are PRE specific
(23, 26, 59). We do not see an effect of Trl
mutations on misexpression of the bxd5.1 PRE. However, interpretation of these experiments is complicated by perdurance of
maternally deposited TRL/GAF, which makes it difficult to detect a
zygotic effect of Trl mutants on PRE-mediated silencing.
Despite ambiguities in the published evidence, Trl is an
enhancer of the extra sex combs phenotype of ph (Table 2)
and of Pc (59), supporting a role for
Trl in both silencing and activation.
In vivo the TRL/GAF may have an architectural role in chromatin
structure that allows access to both PcG and trxG proteins, explaining
its dual role. Alternatively, TRL/GAF may be a subunit of activating
and repressing transcription complexes involved in sequence-specific
targeting of both types of complexes. It has been shown that TRL/GAF
interacts with dSAP18 (Sin3-associated polypeptide) and mediates
repression through iab-6, perhaps by recruiting the
Sin3-histone deacetylase complex (16). These two
hypotheses are not mutually exclusive. Further characterization of
complex 2 activity may provide support for either or both hypotheses.
We are not aware of any previous suggestion that Psq has a role in
PcG-mediated silencing. As noted in the results, two psq mutations had no effect on silencing of the bxd5.1 PRE, but
this may be due to maternally deposited protein or mRNA. Nevertheless, psq mutations show strong enhancement of the extra sex combs
phenotype of two PcG mutations, ph and Pc, one of
the defining characteristics of PcG mutations (53). We
conclude that Psq is a novel enhancer of PC with sequence-specific
binding activity.
The complex 2 binding activity of QS0.15 is novel.
Previous
studies have identified two PcG protein complexes in
Drosophila: the PRC1 complex containing the PHP-170 isoform, PC, PSC, and SCM and lacking Enhancer of Zeste [E(Z)]
(49), and a complex containing E(Z) and Extra Sex Combs
(ESC) but not PH (61). Using in vitro protein binding
assays, we have also shown direct interaction between the SAM domains
of PH and SCM (42). Consequently, it might be expected
that a binding activity containing PHP should contain PC, PSC, or SCM.
However, a number of observations support the conclusion that the
complex 2 binding activities present in QS0.15 represent novel PcG
activities. First, PC, PSC, and SCM are not present in the QS0.15
fraction that contains the MHS-70 binding activities. Second, the PH
isoform, PHP-170, that coimmunoprecitates with PC and is reported in
PRC1 (49) is not present in QS0.15. Third, PRC1 does not
contain TRL/GAF (49), which is present in complex 2, as
shown by supershift analysis, and in QS0.15, as shown by Western
analysis. Fourth, the complex 2 binding activities present in QS0.15
are sequence specific, whereas the DNA binding activities of PRC1 are
unknown. Fifth, the complex 2 activity is chromatographically distinct from PRC1 which elutes in BR0.85 (data not shown). The complex 2 activity is also distinct from the BP binding activity (Fig. 1A),
previously identified in coimmunoprecipitation experiments which
contains PC and TRL/GAGA (26), as QS0.15 does not contain PC. The MHS-70 complex 2 activity therefore represents a novel PcG
sequence-specific activity containing distinct isoforms of PHP,
TRL/GAF, and Psq, which may be involved in site-specifically targeting
repressive complexes to the bxd PRE. Experiments are currently in progress to determine the subunit composition of more
highly fractionated complex 2 activity (Hodgson and Brock, unpublished).
Complex organization of the M element.
Previous studies on the
structural organization of the bxd1.5 PRE (M element)
revealed three regions: a 661-bp pairing-sensitive fragment which
contained distinct PHO binding sites, and PC-containing DNA binding
activities flanked upstream by a 354-bp fragment and downstream by a
485-bp fragment (DPS) which contained PHO sites (marked in sites BP and
MPH-75 in Fig. 1) (20, 26, 53). Our results identify two
additional sites (MHS-70 and MPA-168) located within the DPS fragment
required for maintenance of silencing (Fig. 1). These observations are
in keeping with the idea that the M element is built up from sites with
differing functions (26).
A limited region of the M element is required for pairing-sensitive
repression that is separable from regions required for embryonic
silencing (26). This conclusion is supported by similar observations in the iab-2 regulatory region of
abdominal-A. The sequences required for pairing-sensitive
repression by the iab-2 PRE are not sufficient for embryonic
silencing, which requires additional sequences in the iab-2
enhancer (50). Consistent with this observation, deletion
of MHS-70 and MPA-168, which lie outside the pairing-sensitive region
of the bxd5.1 PRE, have no effect on pairing-sensitive
repression by bxd5.1 (B. Argiropoulos and H. W. Brock,
unpublished results).
Modular organization of the bxd PRE.
Genetic
evidence shows that mutations in many PcG genes causes derepression of
the bxd PRE (55). It has been shown that distinct fragments of the bxd PRE respond differentially to
different PcG mutations (26, 62), supporting the idea that
this PRE is recognized by multiple PcG binding activities. This idea is strongly supported by observations that antibodies to PC and PSC preferentially precipitate different fragments of the M element in
vitro (26). As we argue above, we show that even within
the MHS-70 element, there are recognition sequences for at least two distinct binding activities, neither of which contains PC.
Our results are inconsistent with a model which posits that PHO is the
primary recognition and PcG recruitment factor for the bxd
PRE. The MHS-70 fragment, which does not contain PHO sites, is required
for maintenance of embryonic silencing, ruling out a role for PHO on
this fragment. The results of the MHS-70 competition experiments also
rule out a model in which PHO binding recruits PcG proteins which cause
a change in chromatin structure that spreads from PHO binding sites,
independent of the flanking DNA sequences. Instead, these results
support a model in which PRE function is built up from sequences with
different functions, that recognize specific binding activities which
contribute to the overall function of the PRE. This organization may be
analogous to the modular organization of viral and cellular enhancers
(14).
 |
ACKNOWLEDGMENTS |
We thank D. Hogness and J. Mueller for providing clones from the
Ubx regulatory region; P. Becker and C. Wu for the gift of anti-TRL/GAF antibody; C. Berg for anti-Psq antibody and mutant fly
strains; P. O'Farrell, J. Simon, and J.-M. Dura for antibodies to PC,
SCM, and PSC, respectively; P. Adler for the Su(Z)2 cDNA construct; and
M. Biggin for mutant Trl fly strains. We thank L. Matsuuchi
for discussions on the precipitin reaction and members of the Brock lab
for critical comments on the manuscript. We thank V. Pirrotta and
members of his lab for sharing information prior to publication and for
stimulating discussion.
This work was supported by a grant from the Medical Research council of
Canada to H.W.B.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Zoology, University of British Columbia, 6270 University Blvd.,
Vancouver, BC, Canada V6T 1Z4. Phone: (604) 822-2619. Fax: (604)
822-2416. E-mail: brock{at}zoology.ubc.ca.
 |
REFERENCES |
| 1.
|
Akam, M.
1987.
The molecular basis for metameric pattern in the Drosophila embryo.
Development
101:1-22[Abstract].
|
| 2.
|
Bender, W.,
M. Akam,
F. Karch,
P. A. Beachy,
M. Peifer,
P. Spierer,
E. B. Lewis, and D. S. Hogness.
1983.
Molecular genetics of the Bithorax complex in Drosophila melanogaster.
Science
221:23-29[Abstract/Free Full Text].
|
| 3.
|
Benyajati, C.,
L. Mueller,
N. Xu,
M. Pappano,
J. Gao,
M. Mosammaparast,
D. Conklin,
H. Granok,
C. Craig, and S. Elgin.
1997.
Multiple isoforms of GAGA factor, a critical component of chromatin structure.
Nucleic Acids Res.
25:3345-3353[Abstract/Free Full Text].
|
| 4.
|
Bhat, K. M.,
G. Farkas,
F. Karch,
H. Gyurkovics,
J. Gausz, and P. Schedl.
1996.
The GAGA factor is required in the early Drosophila embryo not only for transcriptional regulation but also for nuclear division.
Development
122:1513-1522[Abstract].
|
| 5.
|
Biggin, M. D., and R. Tjian.
1988.
Transcription factors that activate the Ultrabithorax promotor in developmentally staged extracts.
Cell
53:699-711[CrossRef][Medline].
|
| 6.
|
Brown, J. L.,
D. Mucci,
M. Whitely,
M.-L. Dirksen, and J. A. Kassis.
1998.
The Drosophila Polycomb Group gene pleiohomeotic encodes a DNA binding protein with homology to the transcription factor YY1.
Mol. Cell
1:1057-1064[CrossRef][Medline].
|
| 7.
|
Busturia, A., and M. Bienz.
1993.
Silencers in Abdominal-B, a homeotic Drosophila gene.
EMBO J.
12:1415-1425[Medline].
|
| 8.
|
Chan, C.-S.,
L. Rastelli, and V. Pirotta.
1994.
A Polycomb response element in the Ubx gene that determines an epigenetically inherited state of repression.
EMBO J.
13:2553-2564[Medline].
|
| 9.
|
Chiang, A.,
M. B. O'Connor,
R. Paro,
J. Simon, and W. Bender.
1995.
Discrete Polycomb-binding sites in each parasegmental domain of the bithorax complex.
Development
121:1681-1689[Abstract].
|
| 10.
|
Christen, B., and M. Bienz.
1994.
Imaginal disc silencers from Ultrabithorax: evidence for Polycomb response elements.
Mech. Dev.
48:255-266[CrossRef][Medline].
|
| 11.
|
DeCamillis, M. A.,
N. Cheng,
D. Pierre, and H. W. Brock.
1992.
The polyhomeotic gene of Drosophila encodes a chromatin protein that shares polytene chromosome binding sites with Polycomb.
Genes Dev.
6:223-232[Abstract/Free Full Text].
|
| 12.
| |